Linked Life Data

19847482

Source:http://linkedlifedata.com/resource/pubmed/id/19847482

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2010-5-12
pubmed:abstractText
The purpose of this study was to compare the ability of multidetector computed tomography (MDCT) and magnetic resonance imaging (MRI) to evaluate treatment results after transarterial chemoembolization (TACE), with a special focus on the influence of Lipiodol on calculation of tumor necrosis according to EASL criteria. A total of 115 nodules in 20 patients (17 males, 3 females; 69.5 +/- 9.35 years) with biopsy-proven hepatocellular carcinoma were treated with TACE. Embolization was performed using a doxorubicin-Lipiodol emulsion (group I) or DC Beads loaded with doxorubicin (group II). Follow-up included triphasic contrast-enhanced 64-row MDCT (collimation, 0.625 mm; slice, 3 mm; contrast bolus, 120 ml iomeprol; delay by bolus trigger) and contrast-enhanced MRI (T1 native, T2 native; five dynamic contrast-enhanced phases; 0.1 mmol/kg body weight gadolinium-DTPA; slice thickness, 4 mm). Residual tumor and the extent of tumor necrosis were evaluated according to EASL. Contrast enhancement within tumor lesions was suspected to represent vital tumor. In the Lipiodol-based TACE protocol, MDCT underestimated residual viable tumor compared to MRI, due to Lipiodol artifacts (23.2% vs 47.7% after first, 11.9% vs 31.2% after second, and 11.4% vs 23.7% after third TACE; p = 0.0014, p < 0.001, and p < 0.001, respectively). In contrast to MDCT, MRI was completely free of any artifacts caused by Lipiodol. In the DC Bead-based Lipiodol-free TACE protocol, MRI and CT showed similar residual tumor and rating of treatment results (46.4% vs 41.2%, 31.9 vs 26.8%, and 26.0% vs 25.6%; n.s.). In conclusion, MRI is superior to MDCT for detection of viable tumor residuals after Lipiodol-based TACE. Since viable tumor tissue is superimposed by Lipiodol artifacts in MDCT, MRI is mandatory for reliable decision-making during follow-up after Lipiodol-based TACE protocols.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1432-086X
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
33
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
532-40
pubmed:meshHeading
pubmed-meshheading:19847482-Aged, pubmed-meshheading:19847482-Antimetabolites, Antineoplastic, pubmed-meshheading:19847482-Artifacts, pubmed-meshheading:19847482-Carcinoma, Hepatocellular, pubmed-meshheading:19847482-Chemoembolization, Therapeutic, pubmed-meshheading:19847482-Contrast Media, pubmed-meshheading:19847482-Doxorubicin, pubmed-meshheading:19847482-Emulsions, pubmed-meshheading:19847482-Female, pubmed-meshheading:19847482-Gadolinium DTPA, pubmed-meshheading:19847482-Humans, pubmed-meshheading:19847482-Iodized Oil, pubmed-meshheading:19847482-Iopamidol, pubmed-meshheading:19847482-Linear Models, pubmed-meshheading:19847482-Liver Neoplasms, pubmed-meshheading:19847482-Magnetic Resonance Imaging, pubmed-meshheading:19847482-Male, pubmed-meshheading:19847482-Necrosis, pubmed-meshheading:19847482-Prospective Studies, pubmed-meshheading:19847482-Tomography, X-Ray Computed, pubmed-meshheading:19847482-Treatment Outcome
pubmed:year
2010
pubmed:articleTitle
MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma.
pubmed:affiliation
Department of Diagnostic and Interventional Radiology, Johannes Gutenberg-University of Mainz, Langenbeckstrasse 1, 55131 Mainz, Germany. Roman.Kloeckner@googlemail.com
pubmed:publicationType
Journal Article, Comparative Study